Heart failure & cardiomyopathies
Circulating MicroRNAs Identify Early Phenotypic Changes in Sarcomeric Hypertrophic Cardiomyopathy
Authors' conclusion
Circulating miRNAs may augment the clinical stratification of HCM and improve understanding of the transition from health to disease in sarcomere gene variant carriers.
Study context
- Population
- Hypertrophic cardiomyopathy (HCM) sarcomere variant carriers with and without a diagnosis of HCM, and healthy controls57 sarcomere variant carriers
- Exposure
- Circulating miRNA profiles across HCM disease stages in sarcomere variant carriers vs healthy controls
- Clinical HCMn = 25
- Subclinical HCM with early phenotypic changesn = 21
- Subclinical HCM without early phenotypic changesn = 11
- Outcome
- Differentially expressed circulating miRNAs between disease stages (arrays for 381 miRNAs, normalised to miRNA-320)
Methodological detailsRandom forest, Wilcoxon rank sum test and logistic regression used to identify differentially expressed microRNAs (miRNAs)
- Random forest, Wilcoxon rank sum test and logistic regression used to identify differentially expressed miRNAs
Main finding
As reported in the abstract
Circulating miRNA profile discrimination
- Differentiated healthy controls from sarcomere variant carriers with subclinical and clinical disease
- Differentiated clinical HCM from subclinical HCM without early phenotypic changes
- Differentiated subclinical HCM with vs without early phenotypic changes
- Did not differentiate clinical HCM from subclinical HCM with early phenotypic changes, suggesting biologic similarity
Observational data: associations, not effects.
Original publication
Circulating MicroRNAs Identify Early Phenotypic Changes in Sarcomeric Hypertrophic Cardiomyopathy. Circ Heart Fail. Published 7 March 2023. doi:10.
Summarised from the published abstract; every number is checked against it